Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma (Alternative)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02689869
Recruitment Status : Active, not recruiting
First Posted : February 24, 2016
Last Update Posted : September 4, 2019
Sponsor:
Collaborators:
Hoffmann-La Roche
Janssen-Cilag G.m.b.H
Information provided by (Responsible Party):
Prof. Dr. Wolfgang Hiddemann, Ludwig-Maximilians - University of Munich

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : April 2022
Estimated Study Completion Date : July 2022